A severe case of bevacizumab-induced thrombotic microangiopathy

Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thromboc...

Full description

Saved in:
Bibliographic Details
Published inJournal of oncology pharmacy practice Vol. 25; no. 7; p. 1754
Main Authors Bektas, Mert, Samancı, Nilay S, Cokgezer, Simay, Keskin, Dilek, Demirelli, Fuat H
Format Journal Article
LanguageEnglish
Published England 01.10.2019
Subjects
dose-dependent
toxicity-mediated drug-induced thrombotic microangiopathy
thrombocytopenia
Bevacizumab
Online AccessGet more information

Cover

More Information
Summary:Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.
ISSN:1477-092X
DOI:10.1177/1078155218800371